Results of pegylated interferon and ribavirin for the treatment of chronic hepatitis C in clinical practice: A 5-year experience;Resultados del tratamiento con interferón pegilado y ribavirina para la hepatitis crónica por el virus C en la práctica clínica. Experiencia de 5 años

Gastroenterologia y Hepatologia

Volumn 31, Issue 5, 2008, Pages 274-279

  Vergara, Mercedes ^a,b,c   Gallach, Marta ^a   Dalmau, Blai ^a,b   Gil, Montserrat ^a,b   Miquel, Mireia ^a   Rudi, Núria ^a   Gavarro, Antoni ^a   Cebollero, Alba ^a   Masip, Montserrat ^a   Real, Jordi ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Servicio de Oncología Médica   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA;

ADULT; ARTICLE; BLOOD TRANSFUSION; BODY WEIGHT; CHRONIC HEPATITIS; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; GENETIC ANALYSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATHOGENESIS; TREATMENT RESPONSE;

EID: 43449099741     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13119878     Document Type: Article

References (26)

1. M. Bruguera X. Forns Hepatitis C in Spain Med Clin (Barc) 127 2006 113 117
2. J.L. Dienstag J.G. McHutchison American Gastroenterological Association technical review on the management of hepatitis C Gastroenterology 130 2006 231 264
3. D.B. Strader T. Wright D.L. Thomas L.B. Seeff Diagnosis, management, and treatment of hepatitis C Hepatology 39 2004 1147 1171
4. M.W. Fried M.L. Shiffman K.R. Reddy C. Smith G. Marinos F.L. Goncales Jr Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
5. S.J. Hadziyannis H. Sette Jr T.R. Morgan V. Balan M. Diago P. Marcellin Peginterferon-alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
6. M.P. Manns J.G. McHutchison S.C. Gordon V.K. Rustgi M. Shiffman R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
7. A. Gervais N. Boyer P. Marcellin Tolerability of treatments for viral hepatitis Drug Saf 24 2001 375 384
8. C.A. Hughes S.D. Shafran Chronic hepatitis C virus management: 2000-2005 update Ann Pharmacother 40 2006 74 82
9. M.P. Manns H. Wedemeyer M. Cornberg Treating viral hepatitis C: efficacy, side effects, and complications Gut 55 2006 1350 1359
10. A.A. Dan L.M. Martin C. Crone J.P. Ong D.W. Farmer T. Wise Depression, anemia and health-related quality of life in chronic hepatitis C J Hepatol 44 2006 491 498
11. J.G. McHutchison M. Manns K. Patel T. Poynard K.L. Lindsay C. Trepo Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C Gastroenterology 123 2002 1061 1069
12. R.G. Knodell K.G. Ishak W.C. Black T.S. Chen R. Craig N. Kaplowitz Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 1981 431 435
13. A.M. Di Bisceglie P. Martin C. Kassianides M. Lisker-Melman L. Murray J. Waggoner Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial N Engl J Med 321 1989 1506 1510
14. T. Poynard P. Marcellin S.S. Lee C. Niederau G.S. Minuk G. Ideo Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 352 1998 1426 1432
15. P. Glue J.W. Fang R. Rouzier-Panis C. Raffanel R. Sabo S.K. Gupta Pegylated interferon-alpha-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group Clin Pharmacol Ther 68 2000 556 567
16. K.L. Lindsay C. Trepo T. Heintges M.L. Shiffman S.C. Gordon J.C. Hoefs A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C Hepatology 34 2001 395 403
17. L. Castera A. Constant C. Henry P. Champbenoit P.H. Bernard J. Demotes-Mainard Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C Aliment Pharmacol Ther 24 2006 1223 1230
18. G.B. Gaeta D.F. Precone F.M. Felaco R. Bruno A. Spadaro G. Stornaiuolo Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in «real world» patients with chronic hepatitis C Aliment Pharmacol Ther 16 2002 1633 1639
19. S.S. Lee V.G. Bain K. Peltekian M. Krajden E.M. Yoshida M. Deschenes Treating chronic hepatitis C with pegylated interferon alfa-2a (40 kD) and ribavirin in clinical practice Aliment Pharmacol Ther 23 2006 397 408
20. A.M. Di Bisceglie J.H. Hoofnagle Optimal therapy of hepatitis C Hepatology 36 2002 121S 127S
21. T. Pieters Marketing medicines through randomised controlled trials: the case of interferon BMJ 317 1998 1231 1233
22. M. Diago A. Olveira R. Sola M. Romero-Gómez R. Moreno-Otero R. Pérez Treatment of chronic hepatitis C genotype 1 with peginterferon-alfa 2a (40 kD) plus ribavirin under routine clinical practice in Spain: early prediction of sustained virological response rate Alimentary Pharmacol Ther 25 2007 899 906
23. T. Fontanges S. Beorchia C. Douvin P. Delassalle J.M. Combis B. Hanslik Safety and efficacy of combination therapy with peginterferon alfa-2a (40 kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection Gastroenterol Clin Biol 31 2007 566 572
24. F. Hasan H. Asker J. Al Khaldi I. Siddique M. Al Ajmi S. Owaid Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 Am J Gastroenterol 99 2004 1733 1737
25. M. Diago T. Hassanein J. Rodes A.M. Ackrill F. Sedarati Optimized virological response in hepatitis C virus genotype 4 with peginterferon-alpha 2a and ribavirin Ann Intern Med 140 2004 72 73
26. W.S. Yeh E.P. Armstrong G.H. Skrepnek D.C. Malone Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a costutility analysis from the perspective of the Veterans Affairs Health Care System Pharmacotherapy 27 2007 813 824